A Be The Match BioTherapies® client was like many allogeneic cell and gene therapy developers. It was developing a therapy for a blood condition and needed to build an off-the-shelf bank of cryopreserved cell sources. The client needed to understand: HLA genotypes to cover most patients in the U.S. How many patients would be covered…
Along with gaining insights into how to tap into the expertise of cord blood banks and access therapy-matched cord blood units (CBUs), you’ll get a better understanding of: Comprehensive benefits of cord blood as an allogeneic cell source for cellular therapy Characteristics and attributes of the existing cord blood inventory Importance of managing logistics for…
Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of: Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes HLA complexity in cell source selection How machine…
Watch this on-demand webinar for an in-depth discussion on these questions and more. You’ll walk away with insights on navigating the scalability of donor starting material as the allogeneic cell therapy industry grows. PANELISTS Abby Waters, PhD Senior Manager, Solutions Owner Be The Match BioTherapies Dean A. Lee, MD, PhD Physician, Hematology and Oncology Director…
Navigating international regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where they diverge.…
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. During this hour long on-demand webinar, our panelists discuss: Why it’s essential to have a good understanding of critical starting…
Considerations for developing scalable and efficient collection network processes The decisions you make when selecting apheresis centers to collect source material for your cell or gene therapy impact your ability to efficiently scale your processes. When your processes and protocols differ from those at an apheresis center, delays can occur. Following best practices can help.…
The ONE Forum 2021: On-demand session Over the last several years, there has been increasing global investment in the development of novel allogeneic cell and gene therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 allogeneic cellular therapies are under development across the globe, many of which are…
On-demand webinar offers actionable insights as you develop your protocols. Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. When collection processes or protocols differ from those in place at a center, there are likely implications for training, forms and standard operating procedures. This…
